La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Bausch + Lomb Gestion

Gestion contrôle des critères 0/4

Le PDG Bausch + Lomb's est Brent Saunders, nommé en Mar2023, a un mandat de 1.42 ans. La rémunération annuelle totale est $ 45.31M, composée du salaire de 3.1% et des bonus 96.9%, y compris les actions et options de la société. détient directement 0.009% des actions de la société, d'une valeur de € 465.25K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.4 ans et 2.3 ans.

Informations clés

Brent Saunders

Directeur général

US$45.3m

Rémunération totale

Pourcentage du salaire du PDG	3.1%
Durée du mandat du directeur général	1.6yrs
Propriété du PDG	0.009%
Durée moyenne d'occupation des postes de direction	1.5yrs
Durée moyenne du mandat des membres du conseil d'administration	2.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Brent Saunders a-t-elle évolué par rapport aux bénéfices de Bausch + Lomb?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$456m
Mar 31 2024	n/a	n/a	-US$337m
Dec 31 2023	US$45m	US$1m	-US$260m

Rémunération vs marché: La rémunération totale de Brent ($USD 45.31M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 3.47M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Brent avec les performances de l'entreprise.

PDG

Brent Saunders (54 yo)

1.6yrs

Titularisation

US$45,309,051

Compensation

Mr. Brenton L. Saunders, J. D., also known as Brent, is CEO & Chairman of the Board at Bausch & Lomb Incorporated since 2023. He is CEO & Chairman of the Board at Bausch + Lomb Corporation since March 06,...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Brenton L. Saunders	CEO & Chairman	1.6yrs	US$45.31m	0.0092% € 621.3k
Osama Eldessouky	Executive VP & CFO	2.8yrs	US$4.76m	0.024% € 1.7m
A. Robert Bailey	Executive VP & Chief Legal Officer	1.5yrs	US$5.21m	0.0086% € 584.0k
Yehia Hashad	Executive VP of Research & Development and Chief Medical officer	2.8yrs	US$2.66m	0.011% € 724.4k
Andrew Stewart	President of Global Pharmaceuticals & International Consumer	1.8yrs	US$1.93m	0.0020% € 137.0k
Alan Waterhouse	Executive VP and Chief Supply Chain & Operations Officer	1.8yrs	pas de données	pas de données
Frederick Munsch	Senior VP	no data	pas de données	0.0050% € 340.5k
Jonathon Kellerman	Chief Compliance Officer	1.2yrs	pas de données	pas de données
T.J. Crawford	Chief Communications Officer	1.3yrs	pas de données	pas de données
Manisha Narasimhan	Chief Corporate Development & Digital Officer	1.3yrs	pas de données	pas de données
Asli Gevgilili	Executive VP & Chief Human Resources Officer	1.2yrs	pas de données	pas de données
Luc Bonnefoy	President of Surgical	no data	pas de données	0.0034% € 231.3k

1.5yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de S2L n'est pas considérée comme expérimentée (ancienneté moyenne 1.4 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Brenton L. Saunders	CEO & Chairman	1.6yrs	US$45.31m	0.0092% € 621.3k
Thomas Ross	Lead Independent Director	1.6yrs	US$396.30k	0.0036% € 240.8k
John Paulson	Independent Director	2.5yrs	US$312.46k	0.0094% € 636.9k
Sarah Kavanagh	Independent Director	2.5yrs	US$337.50k	0.0053% € 359.5k
Brett Icahn	Independent Director	2.3yrs	US$312.50k	0.0074% € 503.3k
Russel Robertson	Independent Director	2.5yrs	US$327.45k	0.0016% € 111.9k
Andrew von Eschenbach	Independent Director	2.5yrs	US$327.50k	0.0072% € 488.4k
Karen Ling	Independent Director	less than a year	pas de données	0.00075% € 50.9k
Nathalie Bernier	Independent Director	2.5yrs	US$324.95k	0.0098% € 667.5k
Gaoxiang Hu	Independent Director	2.3yrs	US$335.00k	0.0074% € 503.3k

2.4yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de S2L ne sont pas considérés comme expérimentés (ancienneté moyenne 2.3 ans), ce qui suggère un nouveau conseil d'administration.

Bausch + Lomb Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

CEO & Chairman recently bought €460k worth of stock

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation Announces Executive Changes

Recent updates

Bausch + Lomb Corporation Receives FDA Approval for Envista Envy Full Range of Vision Intraocular Lens

Bausch + Lomb Corporation to Report Q3, 2024 Results on Oct 30, 2024

Bausch + Lomb Corporation Launches Opal Digital Marketplace in the United States

New minor risk - Share price stability

CEO & Chairman recently bought €460k worth of stock

Second quarter 2024 earnings released: US$0.43 loss per share (vs US$0.091 loss in 2Q 2023)

Bausch + Lomb Corporation Revises Earnings Guidance for the Full Year 2024

Bausch + Lomb Corporation to Report Q2, 2024 Results on Jul 31, 2024

Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses

Bausch + Lomb Corporation Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States

Bausch + Lomb Corporation Receives Health Canada Approval for Envista Envy™? Full Visual Range Intraocular Lens

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.26 loss in 1Q 2023)

Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Bausch + Lomb Corporation to Report Q1, 2024 Results on May 01, 2024

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Full year 2023 earnings released: US$0.74 loss per share (vs US$0.017 profit in FY 2022)

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2024

Bausch + Lomb Corporation to Report Q4, 2023 Results on Feb 21, 2024

Bausch + Lomb Corporation Receives FDA Approval for TENEO Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

New major risk - Financial position

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.051 loss in 3Q 2022)

Bausch + Lomb Corporation Raises Revenue Guidance for the Full Year of 2023

Bausch + Lomb Will Present New Scientific Data and Analyses At American Academy of Ophthalmology Annual Meeting

Bausch + Lomb Corporation to Report Q3, 2023 Results on Nov 01, 2023

Bausch + Lomb Corporation Launches LUMIFY EYE ILLUMINATIONS in the United States

Bausch + Lomb Corporation Launches MIEBO (Perfluorohexyloctane Ophthalmic Solution) in the United States

Second quarter 2023 earnings released: US$0.091 loss per share (vs US$0.014 profit in 2Q 2022)

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation to Report Q2, 2023 Results on Aug 02, 2023

Bausch + Lomb Corporation (NYSE:BLCO) agreed to acquire Blink® product line of eye and contact lens drops of Johnson & Johnson Vision for approximately $110 million.

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

Bausch + Lomb Corporation to Present the Results of 11 Scientific Poster Presentations Inviding the Company's Consumer, Vision Care and Pharmaceutical Products

Now 20% undervalued

Bausch + Lomb Corporation Launches Biotrue Hydration Boost Contact Lens Rehydrating Drops in the United States

Bausch + Lomb Corporation Launches Bausch + Lomb Infuse®? Multifocal Silicone Hydrogel Contact Lenses in the United States

Bausch + Lomb Corporation Announces Executive Changes

Now 21% undervalued

Bausch + Lomb Corporation and Novaliq Announce Fda Approval of Miebo™? (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Bausch + Lomb and Modulight Announces FDA Approval of ML6710i Photodynamic Laser

Bausch + Lomb Corporation, Annual General Meeting, Apr 24, 2023

Bausch + Lomb Corporation to Report Q4, 2022 Results on Feb 22, 2023

Bausch + Lomb Corporation (NYSE:BLCO) acquired AcuFocus, Inc.

Bausch + Lomb Corporation Announces the U.S. Introduction of Preservision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb Corporation Enters into CEO Separation Agreement with Joseph C. Papa

Bausch + Lomb Corporation Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

Third quarter 2022 earnings released

Bausch + Lomb Corporation Revises Revenue Guidance for the Year 2022

Bausch + Lomb Corporation Announces Introduction of Project Watson Health Care Products for Dogs in the United States

Bausch + Lomb Corporation to Report Q3, 2022 Results on Nov 02, 2022

Bausch + Lomb Corporation Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation with Vitamin D

Bausch + Lomb and Novaliq GmbH Announces U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)

Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.13 in 2Q 2021)

Bausch + Lomb Corporation Reaffirms Earnings Guidance for the Full Year 2022

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration